Vascular risk factors and erectile dysfunction in a cohort of healthy men

Ponholzer, Anton; Temml, Christian; Rauchenwald, Michael; Madersbacher, Stephan

doi:10.1038/sj.ijir.3901468

Cited by 31 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Former users were defined as those who had stopped any of these habits for at least 1 year before interview [34], [35]. Hypertension was defined by a systolic blood pressure (SBP) of ≥140 mmHg or a diastolic blood pressure (DBP) of ≥90 mmHg, while hyperlipidemia was defined by a total cholesterol level of ≥200 mg/dL or a triglycerides level of ≥200 mg/dL [3], [36]. DM was diagnosed when the fasting blood glucose (FBG) was ≥126 mg/dL.…”

Section: Methodsmentioning

confidence: 99%

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

Cheng

Huang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

In addition to adipocytokines, estradiol (E2) and vitamin D have been reported to affect insulin sensitivity, glucose homeostasis and body weight. However, studies about the impact of E2 and vitamin D on metabolic syndrome (MetS) are still limited. The aim of this study is to clarify the roles of circulating E2 and vitamin D on the risk of MetS in middle-aged Taiwanese males. A total of 655 male volunteers, including 243 subjects with MetS (mean age: 56.7±5.8 years) and 412 normal controls (mean age: 55.1±3.6 years), were evaluated. Subjects with MetS had significantly lower circulating E2, 1,25(OH)2D3, and adiponectin, and higher leptin than those without MetS (P<0.001 for all comparisons). E2 and 1,25(OH)2D3 were significantly associated with 4 individual components of MetS; more than adiponectin and leptin that were only associated with 3 individual components. In multivariate regression analysis, E2 (beta = −0.216, P<0.001) and 1,25(OH)2D3 (beta = 0.067, P = 0.045) were still significant predictors of MetS independent of adiponectin and leptin. Further large studies are needed to confirm our preliminary results and elucidate the possible mechanism.

show abstract

Section: Methodsmentioning

confidence: 99%

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

Cheng

Huang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…4-4.9). In this, healthy population, elevated serum lipids were the most important risk factors for the development of ED [48].…”

Section: The Endothelium and Erectile Functionmentioning

confidence: 98%

Dyslipidemia as a Risk Factor for Erectile Dysfunction

Vrentzos¹,

Paraskevas²,

Mikhailidis

2007

CMC

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a common condition with a significant effect on quality of life. The prevalence of ED increases with age and other risk factors (hypertension, diabetes, smoking, coronary heart disease, dyslipidemia and depression). Nitric oxide (NO) activity is adversely affected, in penile and vascular tissue, by these risk factors. Endothelial dysfunction and a reduced generation or bioavailability of NO have emerged as major pathophysiological mechanisms in ED. Hyperlipidemia may impair erectile function by affecting endothelial and smooth muscle cells of the penis. Oxidized low-density lipoprotein is a causative factor for the impaired relaxation response of the corpus cavernosum. Elevated serum cholesterol and reduced high density lipoprotein cholesterol levels are associated with an increased risk of ED. It follows that treating dyslipidemia could have a beneficial effect on ED. Phosphodiesterase type 5 inhibitors are now considered as first line treatment for ED. There is evidence that statins improve responses to these drugs. ED is considered as a warning sign of silent or early vascular disease. The use of statins may be beneficial in these patients.

show abstract

“…Hypertension was defined by a systolic pressure of ≥140 mmHg or diastolic pressure of ≥90 mmHg. Hyperlipidaemia was defined by a total cholesterol level of ≥200 mg/dL or triglycerides level of ≥200 mg/dL [16]. Patients with a history of hypertension, DM, or hyperlipidaemia, but under control by regular medication were also included.…”

Section: Methodsmentioning

confidence: 99%

The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α₁‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo prospectively investigate the association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective a 1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms (BPH/LUTS), as nitric oxide has recently gained increasing recognition as an important neurotransmitter of functions in the lower urinary tract. Patients and MethodsIn all, 136 men with BPH/LUTS were recruited from urology outpatient clinics in a university hospital. Oral therapy with doxazosin gastrointestinal therapeutic system (GITS) 4 mg once-daily was given for 12 weeks. The drug efficacy was assessed by the changes from baseline in the total International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q max ) and post-void residual urine volume (PVR) at 12 weeks of treatment. The 'responders' to doxazosin GITS were defined as those who had a total IPSS decrease of >4 points from baseline. eNOS G894T polymorphism was determined using the polymerase chain reaction-restriction fragment length polymorphism method. ResultsPatients had statistically significant improvements in total IPSS, quality of life score, and Q max (P < 0.01) after a 12-week period of treatment. Using multiple logistic regression analysis adjusted for age and IPSS, our results showed that being a eNOS 894T allele carrier was an independent risk factor for being a drug non-responder (P = 0.03, odds ratio 4.19). Moreover, a decreased responder rate (P = 0.01), as well as the lower improvements in IPSS (P = 0.02) and Q max (P = 0.03) were significantly associated with increment in the T allele number. ConclusionsThe presence of the eNOS 894T allele had a significantly negative impact on responsiveness to a selective a 1 -blocker in BPH/LUTS treatment, suggesting that eNOS G894T gene polymorphism may be a genetic susceptibility factor for a 1 -blocker efficacy in men with BPH/LUTS.

show abstract

Vascular risk factors and erectile dysfunction in a cohort of healthy men

Cited by 31 publications

References 20 publications

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

Dyslipidemia as a Risk Factor for Erectile Dysfunction

The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α₁‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms

Contact Info

Product

Resources

About

Vascular risk factors and erectile dysfunction in a cohort of healthy men

Cited by 31 publications

References 20 publications

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

The Impact of Estradiol and 1,25(OH)2D3 on Metabolic Syndrome in Middle-Aged Taiwanese Males

Dyslipidemia as a Risk Factor for Erectile Dysfunction

The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms

Contact Info

Product

Resources

About

The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α₁‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms